Trial Profile
A phase I dose escalation study investigating safety and tolerability of single oral dose of Ndi-010976 in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Firsocostat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- 29 Aug 2020 Results assessing Concentration-QT analysis of firsocostat presented at The International Liver Congress 2020
- 16 May 2016 New trial record
- 17 Apr 2016 Results presented at The International Liver Congress™ 2016.